Evidence map›Paper›PMID 39557773›Full record

SynthesisHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2025

Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis.

Shady Habboush, Navyamani V Kagita, Ahmed F Gadelmawla, Ahmed Elmoursi, Nooraldin Merza, Ahmed A Abdo, Al Hussein M Zahran, Moustafa Eldeib, Alsayed A Almarghany, Mohamed M Abdelfadil and 6 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shady HabboushSaudi German Hospital in Dubai, Dubai, UAE.
Navyamani V KagitaDepartment of Internal Medicine, Mercy Catholic Medical Center, Darby, PA, USA.
Ahmed F GadelmawlaFaculty of Medicine, Menoufia University, Menoufia, Egypt.
Ahmed ElmoursiDepartment of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nooraldin MerzaInternal Medicine Department, University of Toledo, Toledo, OH, USA.
Ahmed A AbdoDepartment of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Al Hussein M ZahranDepartment of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Moustafa EldeibDepartment of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Alsayed A AlmarghanyDepartment of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed M AbdelfadilFaculty of Medicine, Fayoum University, Fayoum, Egypt. Mmm37@fayoum.edu.eg.
Mohamed A AbdelkarimFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Islam ShawkyFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Omar M MohammedFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Abdullah AlharranCollege of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
Mahmoud M AliFaculty of Pharmacy, Al-Azhar University, Assuit, Egypt.
Shereef ElbardisySaudi German Hospital in Dubai, Dubai, UAE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence.

aimThis study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia.

methodsWe searched PubMed, Web of Science, Cochrane, Embase, and Scopus databases for relevant articles matching our inclusion criteria. Following the application of inclusion criteria, four studies were selected for qualitative analysis and four studies for meta-analysis.

resultsOur analysis showed TAR [n = 155] significantly reduced mean systolic blood pressure (MSSBP) at week 4 compared to TR (n = 163) (MD = -15.65 mmHg) and TA (MD = -4.63 mmHg). TAR also showed superiority over all groups (TR [n = 163], TA [n = 162]) in MSSBP reduction. For low-density lipoprotein-cholesterol (LDL-C), TAR only showed a significant difference at week 4 compared to TA (MD = -86.41 mg/dL), with no difference between TAR and TR at either week 4 or 8.

conclusionOur findings suggest that TAR may be a safe and effective therapeutic option for the concurrent management of hypertension and dyslipidemia. However, there is no significant difference regarding adverse events between both arms.

Indexed as

Angiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBlood PressureCalcium Channel BlockersHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionRosuvastatin CalciumAgedAmlodipineBiomarkersDrug CombinationsDrug Therapy, CombinationDyslipidemiasFemaleHumansLipidsAmlodipineAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBiomarkersCalcium Channel BlockersDrug CombinationsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsRosuvastatin CalciumTelmisartantelmisartan amlodipine combinationDyslipidemiaHypertensionTARTelmisartan/amlodipine/rosuvastatinTriple therapy

Identifiers

PMID39557773

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.